What one share of Atara Biotherapeutics holds
Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease.
Atara Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-09-30; the balance sheet is as of 2026-09-30.
| Profit | −$1.00 |
|---|---|
| Cash and investments | $0.40 |
| Book value | −$3.72 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$55.92 | $0.28 | −$36.59 | — | $276.80 |
| 2016 | — | −$68.78 | $2.63 | −$54.86 | — | $219.24 |
| 2017 | — | −$100.03 | $16.94 | −$90.19 | — | $144.70 |
| 2018 | — | −$131.64 | $20.50 | −$123.08 | — | $184.56 |
| 2019 | — | −$141.78 | $2.79 | −$117.60 | — | $127.97 |
| 2020 | — | −$103.63 | $1.53 | −$62.61 | — | $138.64 |
| 2021 | — | −$90.78 | $2.82 | −$61.68 | — | $76.25 |
| 2022 | $15.58 | −$55.96 | $1.03 | −$67.32 | — | $33.00 |
| 2023 | $2.02 | −$65.19 | $0.29 | −$45.85 | — | $23.30 |
| 2024 | $17.22 | −$11.41 | $0.03 | −$9.21 | — | −$16.60 |
| 2025 | $9.50 | $2.57 | $0.00 | −$4.01 | — | −$5.26 |
Common questions about Atara Biotherapeutics
How much does one share of Atara Biotherapeutics earn?
Over the last 12 months, Atara Biotherapeutics lost $1.00 for each share.
Does Atara Biotherapeutics pay a dividend?
Atara Biotherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Atara Biotherapeutics’s book value per share?
Atara Biotherapeutics’s book value is negative (−$3.72 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of September 30, 2026.
How much cash and debt does each share of Atara Biotherapeutics have?
Each share of Atara Biotherapeutics has $0.40 of cash and investments, as of September 30, 2026.
Has Atara Biotherapeutics bought back shares?
Atara Biotherapeutics’s share count rose about 1143% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.